Abstract
Over the last decade, there has been a significant and rapidly growing interest in the use of radiolabeled receptor-binding peptides for both nuclear imaging and targeted radiotherapy. This is underscored by the recent FDA approval of NETSPOT, a peptide labeled with gallium-68 for the PET imaging of neuroendocrine tumors. As small protein fragments, peptides are attractive radiopharmaceuticals for several reasons, notably their ease of synthesis, tolerance of structural modifications for radiolabeling, high affinity and selectivity for receptors, rapid pharmacokinetics, and lack of immunogenicity. A notable drawback for some peptides, however, lies in their low metabolic stability. This chapter describes the overall process for the development of radiolabeled peptides, including their design, radiosynthesis, optimization, and in vitro and in vivo evaluation. In addition, it highlights some of the most exciting recent and future clinical applications of these radiopharmaceuticals.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov Today. 2013;18(17–18):807–17.
Okarvi SM, Maecke HR. Radiolabelled peptides in medical imaging. In: Koutsopoulos S, editor. Peptide applications in biomedicine, biotechnology and bioengineering. Duxford: Woodhead Publishing; 2018. p. 431–83.
Chatalic KLS, Kwekkeboom DJ, de Jong M. Radiopeptides for imaging and therapy: a radiant future. J Nucl Med. 2015;56(12):1809–12.
Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122–8.
Wetzler M, Hamilton P. Peptides as therapeutics. In: Koutsopoulos S, editor. Peptide applications in biomedicine, biotechnology and bioengineering. Duxford: Woodhead Publishing; 2018. p. 215–30.
Correia JD, Paulo A, Raposinho PD, Santos I. Radiometallated peptides for molecular imaging and targeted therapy. Dalton Trans. 2011;40(23):6144–67.
Demoin DW, Wyatt LC, Edwards KJ, Abdel-Atti D, Sarparanta M, Pourat J, et al. PET imaging of extracellular pH in tumors with 64Cu- and 18F-labeled pHLIP peptides: a structure–activity optimization study. Bioconjug Chem. 2016;27(9):2014–23.
van Duijnhoven SMJ, Robillard MS, Nicolay K, Grull H. Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation. J Nucl Med. 2011;52(2):279–86.
Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev. 2006;86(3):805–47.
Maschauer S, Einsiedel J, Hübner H, Gmeiner P, Prante O. 18F- and 68Ga-Labeled neurotensin peptides for PET imaging of neurotensin receptor 1. J Med Chem. 2016;59(13):6480–92.
Haubner R, Maschauer S, Prante O. PET radiopharmaceuticals for imaging integrin expression: Tracers in clinical studies and recent developments. Biomed Res Int. 2014;2014:1–17.
Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev. 2004;24(3):357–97.
Levine R, Krenning EP. Clinical history of the theranostic radionuclide approach to neuroendocrine tumors and other types of cancer: historical review based on an interview of Eric P. Krenning by Rachel Levine. J Nucl Med. 2017;58(Suppl. 2):3S–9S.
Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, et al. The Impact of somatostatin receptor–directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. J Nucl Med. 2017;58(5):756–61.
Jadvar H, Chen X, Cai W, Mahmood U. Radiotheranostics in cancer diagnosis and management. Radiology. 2018;286(2):388–400.
Morgat C, Mishra AK, Varshney R, Allard M, Fernandez P, Hindie E. Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors. J Nucl Med. 2014;55(10):1650–7.
Sah BR, Burger IA, Schibli R, Friebe M, Dinkelborg L, Graham K, et al. Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer. J Nucl Med. 2015;56(3):372–8.
Yu Z, Ananias HJK, Carlucci G, Hoving HD, Helfrich W, Dierckx RAJO, et al. An update of radiolabeled bombesin analogs for gastrin-releasing peptide receptor targeting. Curr Pharm Des. 2013;19(18):3329–41.
Danhier F, Le Breton A, Preat V. RGD-Based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm. 2012;9(11):2961–73.
Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22.
Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science. 1987;238(4826):491–7.
Haubner R, Decristoforo C. Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Front Biosci. 2009;14:872–86.
Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging. 2012;39:126–38.
Gagnon MKJ, Hausner SH, Marik J, Abbey CK, Marshall JF, Sutcliffe JL. High-throughput in vivo screening of targeted molecular imaging agents. Proc Natl Acad Sci U S A. 2009;106(42):17904–9.
Bandyopadhyay A, Raghavan S. Defining the role of integrin alpha(v)beta(6) in cancer. Curr Drug Targets. 2009;10(7):645–52.
Hackel BJ, Kimura RH, Miao Z, Liu H, Sathirachinda A, Cheng Z, et al. 18F-Fluorobenzoate-labeled cystine knot peptides for PET imaging of integrin alpha(v)beta(6). J Nucl Med. 2013;54(7):1101–5.
Hausner SH, Bauer N, Hu LY, Knight LM, Sutcliffe JL. The effect of bi-terminal PEGylation of an integrin alpha(v)beta(6)-targeted 18F peptide on pharmacokinetics and tumor uptake. J Nucl Med. 2015;56(5):784–90.
Li S, McGuire MJ, Lin M, Liu YH, Oyama T, Sun X, et al. Synthesis and characterization of a high-affinity alpha(v)beta(6)-specific ligand for in vitro and in vivo applications. Mol Cancer Ther. 2009;8(5):1239–49.
Charron CL, Hickey JL, Nsiama TK, Cruickshank DR, Turnbull WL, Luyt LG. Molecular imaging probes derived from natural peptides. Nat Prod Rep. 2016;33(6):761–800.
Aumailley M, Gurrath M, Müller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapoptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 1991;291(1):50–4.
Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12(1):697–715.
Haubner R, Finsinger D, Kessler H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the alpha(v)beta(3) integrin for a new cancer therapy. Angew Chem Int Ed Engl. 1997;36(1314):1374–89.
Burgus R, Ling N, Butcher M, Guillemin R. Primary structure of somatostatin, a hypothalamic peptide that inhibits the secretion of pituitary growth hormone. Proc Natl Acad Sci U S A. 1973;70(3):684–8.
Anastasi A, Erspamer V, Bucci M. Isolation and structure of bombesin and alytesin, two analogous active peptides from skin of European amphibians Bombina and Alytes. Experientia. 1971;27(2):166–7.
Logan D, Abughazaleh R, Blakemore W, Curry S, Jackson T, King A, et al. Structure of a major immunogenic site on foot-and-mouth-disease virus. Nature. 1993;362(6420):566–8.
Fani M, Maecke HR. Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging. 2012;39(S1):11–30.
Hu LY, Kelly KA, Sutcliffe JL. High-throughput approaches to the development of molecular imaging agents. Mol Imaging Biol. 2017;2:163–82.
Liu R, Li X, Xiao W, Lam KS. Tumor-targeting peptides from combinatorial libraries. Adv Drug Deliv Rev. 2017;110–111:13–37.
Aina OH, Liu RW, Sutcliffe JL, Marik J, Pan CX, Lam KS. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm. 2007;4(5):631–51.
Amblard M, Fehrentz J-A, Martinez J, Subra G. Methods and protocols of modern solid phase peptide synthesis. Mol Biotechnol. 2006;33(3):239–54.
Shelton PT, Jensen KJ. Linkers, resins, and general procedures for solid-phase peptide synthesis. In: Jensen KJ, Shelton PT, Pedersen S, editors. Peptide synthesis and applications. methods in molecular biology (methods and protocols), vol. 1047. Totowa: Humana Press; 2013. p. 23–41.
Koutsopoulos S. Peptide applications in biomedicine, biotechnology and bioengineering. Duxford: Woodhead Publishing; 2018.
Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4–27.
Boas U, Mirsharghi S. Color test for selective detection of secondary amines on resin and in solution. Org Lett. 2014;16(22):5918–21.
Galati R, Verdina A, Falasca G, Chersi A. Increased resistance of peptides to serum proteases by modification of their amino groups. Z Naturforsch C. 2003;58(7–8):558–61.
Sutcliffe-Goulden JL, O’Doherty MJ, Marsden PK, Hart IR, Marshall JF, Bansal SS. Rapid solid phase synthesis and biodistribution of 18F-labelled linear peptides. Eur J Nucl Med Mol Imaging. 2002;29(6):754–9.
Davis RA, Lau K, Hausner SH, Sutcliffe JL. Solid-phase synthesis and fluorine-18 radiolabeling of cycloRGDyK. Org Biomol Chem. 2016;14(37):8659–63.
Petrou C, Sarigiannis Y. Peptide synthesis: methods, trends, and challenges. In: Koutsopoulos S, editor. Peptide applications in biomedicine, biotechnology and bioengineering. Duxford: Woodhead Publishing; 2018. p. 1–21.
Zhang G, Annan RS, Carr SA, Neubert TA. Overview of peptide and protein analysis by mass spectrometry. Curr Protoc Mol Biol. 2014;108:10.21.1–10.21.30.
Beck JG, Frank AO, Kessler H. NMR of peptides. In: Bertini I, McGreevy KS, Parig G, editors. NMR of biomolecules. Weinheim: Wiley-VCH; 2012. p. 328–44.
Westermann JC, Craik DJ. NMR in peptide drug development. In: Otovos L, editor. Peptide-based drug design. Methods in molecular biology, vol. 494. Totowa: Humana Press; 2008. p. 87–113.
Sabet A, Biersack HJ, Ezziddin S. Advances in peptide receptor radionuclide therapy. Semin Nucl Med. 2016;46(1):40–6.
Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, et al. Noninvasive visualization of the activated alpha(v)beta(3) integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2005;2(3):e70.
Kuchar M, Pretze M, Kniess T, Steinbach J, Pietzsch J, Löser R. Site-selective radiolabeling of peptides by 18F-fluorobenzoylation with [18F]SFB in solution and on solid phase: a comparative study. Amino Acids. 2012;43(4):1431–43.
Richter S, Wuest F. 18F-Labeled peptides: The future is bright. Molecules. 2014;19(12):20536–56.
Eberle AN, Mild G. Receptor-mediated tumor targeting with radiopeptides. J Recept Signal Transduct Res. 2009;29(1):1–37.
Miller PW, Long NJ, Vilar R, Gee AD. Synthesis of C-11, F-18, O-15, and N-13 radiolabels for positron emission tomography. Angew Chem Int Ed Engl. 2008;47(47):8998–9033.
Link JM, Shoner SC, Krohn KA. Sources of carrier F-19 in F-18 fluoride. AIP Conf Proc. 2012;1509(61):61–5. https://doi.org/10.1063/1.4773941.
Okarvi SM. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med. 2001;28(7):929–38.
Olberg DE, Hjelstuen OK. Labeling strategies of peptides with 18F for positron emission tomography. Curr Top Med Chem. 2010;10(16):1669–79.
Krishnan HS, Ma L, Vasdev N, Liang SH. 18F-Labeling of sensitive biomolecules for positron emission tomography. Chemistry. 2017;23(62):15553–77.
Vaidyanathan G, Zalutsky MR. Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F. Nat Protoc. 2006;1(4):1655–61.
Namavari M, Cheng Z, Zhang R, De A, Levi J, Hoerner JK, et al. A novel method for direct site-specific radiolabeling of peptides using [18F]FDG. Bioconjug Chem. 2009;20(3):432–6.
Carberry P, Carpenter AP, Kung HF. Fluoride-18 radiolabeling of peptides bearing an aminooxy functional group to a prosthetic ligand via an oxime bond. Bioorg Med Chem Lett. 2011;21(23):6992–5.
Hausner SH, Marik J, Gagnon MKJ, Sutcliffe JL. In vivo positron emission tomography (PET) imaging with an alpha(v)beta(6) specific peptide radiolabeled using 18F-“click” chemistry: Evaluation and comparison with the corresponding 4-[18F]fluorobenzoyl- and 2-[18F]fluoropropionyl-peptides. J Med Chem. 2008;51(19):5901–4.
Vaidyanathan G, Zalutsky MR. Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F]fluorobenzoate. Int J Rad Appl Instrum B. 1992;19(3):275–81.
Thonon D, Goblet D, Goukens E, Kaisin G, Paris J, Aerts J, et al. Fully automated preparation and conjugation of N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) with RGD peptide using a GE FASTlab synthesizer. Mol Imaging Biol. 2011;13(6):1088–95.
Mäding P, Füchtner F, Wüst F. Module-assisted synthesis of the bifunctional labelling agent N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB). Appl Radiat Isot. 2005;63(3):329–32.
Haka MS, Kilbourn MR, Watkins GL, Toorongian SA. Aryltrimethylammonium trifluoromethanesulfonates as precursors to aryl [18F]fluorides: Improved synthesis of [18F]GBR-13119. J Labelled Comp Radiopharm. 1989;27(7):823–33.
Basuli F, Zhang X, Woodroofe CC, Jagoda EM, Choyke PL, Swenson RE. Fast indirect fluorine-18 labeling of protein/peptide using the useful 6-fluoronicotinic acid-2,3,5,6-tetrafluorophenyl prosthetic group: A method comparable to direct fluorination. J Labelled Comp Radiopharm. 2017;60(3):168–75.
Olberg DE, Arukwe JM, Grace D, Hjelstuen OK, Solbakken M, Kindberg GM, et al. One step radiosynthesis of 6-[18F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester ([18F]F-Py-TFP): A new prosthetic group for efficient labeling of biomolecules with fluorine-18. J Med Chem. 2010;53(4):1732–40.
Wu Z, Li Z-B, Chen X. 18F-labeling of peptides using FBEM. Protoc Exch. 2007; https://doi.org/10.1038/nprot.2007.286.
Wuest F, Köhler L, Berndt M, Pietzsch J. Systematic comparison of two novel, thiol-reactive prosthetic groups for 18F labeling of peptides and proteins with the acylation agent succinimidyl-4-[18F]fluorobenzoate ([18F]SFB). Amino Acids. 2009;36(2):283–95.
White JB, Hausner SH, Carpenter RD, Sutcliffe JL. Optimization of the solid-phase synthesis of F-18 radiolabeled peptides for positron emission tomography. Appl Radiat Isot. 2012;70(12):2720–9.
Bernard-Gauthier V, Lepage ML, Waengler B, Bailey JJ, Liang SH, Perrin DM, et al. Recent advances in F-18 radiochemistry: a focus on B-18F, Si-18F, Al-18F, and C-18F radiofluorination via spirocyclic iodonium ylides. J Nucl Med. 2018;59(4):568–72.
Smith GE, Sladen HL, Biagini SC, Blower PJ. Inorganic approaches for radiolabelling biomolecules with fluorine-18 for imaging with positron emission tomography. Dalton Trans. 2011;40(23):6196–205.
Bernard-Gauthier V, Wängler C, Schirrmacher E, Kostikov A, Jurkschat K, Wängler B, et al. 18F-labeled silicon-based fluoride acceptors: potential opportunities for novel positron emitting radiopharmaceuticals. Biomed Res Int. 2014;2014:1–20.
Wangler C, Niedermoser S, Chin J, Orchowski K, Schirrmacher E, Jurkschat K, et al. One-step 18F-labeling of peptides for positron emission tomography imaging using the SiFA methodology. Nat Protoc. 2012;7(11):1946–55.
Liu Z, Pourghiasian M, Radtke MA, Lau J, Pan J, Dias GM, et al. An organotrifluoroborate for broadly applicable one-step 18F-labeling. Angew Chem Int Ed Engl. 2014;53(44):11876–80.
McBride WJ, Sharkey RM, Goldenberg DM. Radiofluorination using aluminum-fluoride (Al18F). EJNMMI Res. 2013;3(1):36.
Marik J, Sutcliffe JL. Click for PET: rapid preparation of [18F]fluoropeptides using CuI catalyzed 1,3-dipolar cycloaddition. Tetrahedron Lett. 2006;47(37):6681–4.
Glaser M, Årstad E. “Click labeling” with 2-[18F]fluoroethylazide for positron emission tomography. Bioconjug Chem. 2007;18(3):989–93.
Zeng D, Zeglis BM, Lewis JS, Anderson CJ. The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals. J Nucl Med. 2013;54(6):829–32.
Pretze M, Pietzsch D, Mamat C. Recent trends in bioorthogonal click-radiolabeling reactions using fluorine-18. Molecules. 2013;18(7):8618–65.
Kettenbach K, Schieferstein H, Ross TL. 18F-labeling using click cycloadditions. Biomed Res Int. 2014;2014:1–16.
Denk C, Svatunek D, Filip T, Wanek T, Lumpi D, Fröhlich J, et al. Development of a 18F-labeled tetrazine with favorable pharmacokinetics for bioorthogonal PET imaging. Angew Chem Int Ed Engl. 2014;53:9655–9.
Lazari M, Collins J, Shen B, Farhoud M, Yeh D, Maraglia B, et al. Fully automated production of diverse 18F-labeled PET tracers on the ELIXYS multireactor radiosynthesizer without hardware modification. J Nucl Med Technol. 2014;42(3):203–10.
Collet C, Maskali F, Clement A, Chretien F, Poussier S, Karcher G, et al. Development of 6-[18F]fluoro-carbohydrate-based prosthetic groups and their conjugation to peptides via click chemistry. J Labelled Comp Radiopharm. 2016;59(2):54–62.
Jacobson O, Yan X, Ma Y, Niu G, Kiesewetter DO, Chen X. Novel method for radiolabeling and dimerizing thiolated peptides using [18F]-hexafluorobenzene. Bioconjug Chem. 2015;26(10):2016–20.
Ackermann U, Plougastel L, Goh YW, Yeoh SD, Scott AM. Improved synthesis of [18F]FLETT via a fully automated vacuum distillation method for [18F]2-fluoroethyl azide purification. Appl Radiat Isot. 2014;94:72–6.
Ackermann U, Plougastel L, Wichmann C, Goh YW, Yeoh SD, Poniger SS, et al. Fully automated synthesis and coupling of [18F]FBEM to glutathione using the iPHASE FlexLab module. J Labelled Comp Radiopharm. 2014;57(2):115–20.
Zeglis BM, Lewis JS. A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Trans. 2011;40(23):6168–95.
Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110(5):2858–902.
Färber SF, Wurzer A, Reichart F, Beck R, Kessler H, Wester H-J, et al. Therapeutic radiopharmaceuticals targeting integrin alpha(v)beta(6). ACS Omega. 2018;3(2):2428–36.
Roosenburg S, Laverman P, Joosten L, Cooper MS, Kolenc-Peitl PK, Foster JM, et al. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with 64Cu, 68Ga, and 111In. Mol Pharm. 2014;11(11):3930–7.
Hu LY, Bauer N, Knight LM, Li Z, Liu S, Anderson CJ, et al. Characterization and evaluation of 64Cu-labeled A20FMDV2 conjugates for imaging the integrin alpha(v)beta(6). Mol Imaging Biol. 2014;16(4):567–77.
Lin M, Welch MJ, Lapi SE. Effects of chelator modifications on 68Ga-labeled [Tyr3]octreotide conjugates. Mol Imaging Biol. 2013;15(5):606–13.
Cai Z, Anderson CJ. Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals. J Labelled Comp Radiopharm. 2014;57(4):224–30.
De León-Rodríguez LM, Kovacs Z. The synthesis and chelation chemistry of DOTA−peptide conjugates. Bioconjug Chem. 2008;19(2):391–402.
Liu S, Edwards DS. Stabilization of 90Y-labeled DOTA-biomolecule conjugates using gentisic acid and ascorbic acid. Bioconjug Chem. 2001;12(4):554–8.
Banerjee S, Pillai MRA, Knapp FF. Lutetium-177 therapeutic radiopharmaceuticals: Linking chemistry, radiochemistry, and practical applications. Chem Rev. 2015;115(8):2934–74.
Kiesewetter DO, Gao H, Ma Y, Niu G, Quan Q, Guo N, et al. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging. 2011;39(3):463–73.
James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012;92(2):897–965.
Bigott-Hennkens HM, Dannoon S, Lewis MR, Jurisson SS. In vitro receptor binding assays: general methods and considerations. Q J Nucl Med Mol Imaging. 2008;52(3):245–53.
Jenssen H, Aspmo SI. Serum stability of peptides. In: Otvos L, editor. Peptide-based drug design. Methods In molecular biology, vol. 494. Totowa: Humana Press; 2008. p. 177–86.
Hein P, Michel MC, Leineweber K, Wieland T, Wettschureck N, Offermanns S. Receptor and binding studies. In: Dhein S, Mohr FW, Delmar M, editors. Practical methods in cardiovascular research. Berlin: Springer; 2005. p. 723–83.
Walker MW, Miller RJ. 125I-neuropeptide Y and 125I-peptide YY bind to multiple receptor sites in rat brain. Mol Pharm. 1988;34(6):779–92.
Waterhouse R. Determination of lipophilicity and its use as a predictor of blood–brain barrier penetration of molecular imaging agents. Mol Imaging Biol. 2003;5(6):376–89.
Richter S, Wuest M, Bergman CN, Way JD, Krieger S, Rogers BE, et al. Rerouting the metabolic pathway of 18F-labeled peptides: the influence of prosthetic groups. Bioconjug Chem. 2015;26(2):201–12.
Stout DB, Chatziioannou AF, Lawson TP, Silverman RW, Gambhir SS, Phelps ME. Small animal imaging center design: the facility at the UCLA Crump Institute for Molecular Imaging. Mol Imaging Biol. 2005;7(6):393–402.
David JM, Knowles S, Lamkin DM, Stout DB. Individually ventilated cages impose cold stress on laboratory mice: a source of systemic experimental variability. J Am Assoc Lab Anim Sci. 2013;52(6):738–44.
Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36(10):1836–9.
Visser EP, Boerman OC, Oyen WJG. SUV: from silly useless value to smart uptake value. J Nucl Med. 2010;51(2):173–5.
Pompili L, Porru M, Caruso C, Biroccio A, Leonetti C. Patient-derived xenografts: a relevant preclinical model for drug development. J Exp Clin Cancer Res. 2016;35(189):1–8.
Jackson SJ, Thomas GJ. Human tissue models in cancer research: looking beyond the mouse. Dis Model Mech. 2017;10(8):939–42.
Randall EK. PET-computed tomography in veterinary medicine. Vet Clin North Am Small Anim Pract. 2016;46(3):515–33.
Spriet M, Espinosa P, Kyme AZ, Phillips KL, Katzman SA, Galuppo LD, et al. 18F-sodium fluoride positron emission tomography of the equine distal limb: exploratory study in three horses. Equine Vet J. 2018;50:125–32.
Akizawa H, Uehara T, Arano Y. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv Drug Deliv Rev. 2008;60(12):1319–28.
Sleep D. Albumin and its application in drug delivery. Expert Opin Drug Deliv. 2014;12(5):793–812.
Nock BA, Maina T, Krenning EP, de Jong M. “To serve and protect”: enzyme inhibitors as radiopeptide escorts promote tumor targeting. J Nucl Med. 2013;55(1):121–7.
Pless J. The history of somatostatin analogs. J Endocrinol Invest. 2005;28(11 Suppl International):1–4.
Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits secretion of immunoreactive pituitary growth-gormone. Science. 1973;179(4068):77–9.
Okarvi SM. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat Rev. 2008;34(1):13–26.
Martino MCD, Hofland LJ, Lamberts SWJ. Somatostatin and somatostatin receptors: from basic concepts to clinical applications. In: Martini L, editor. Progress in brain research, vol. 182. Amsterdam: Elsevier; 2010. p. 255–80.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Davis, R.A., Hausner, S.H., Sutcliffe, J.L. (2019). Peptides as Radiopharmaceutical Vectors. In: Lewis, J., Windhorst, A., Zeglis, B. (eds) Radiopharmaceutical Chemistry. Springer, Cham. https://doi.org/10.1007/978-3-319-98947-1_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-98947-1_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-98946-4
Online ISBN: 978-3-319-98947-1
eBook Packages: MedicineMedicine (R0)